Bruker, SISCAPA Assay Tech Study Suggests MALDI-MS Suitable for Clinical Protein Quantitation
January 30, 2012
Bruker, SISCAPA Assay Tech Study Suggests MALDI-MS Suitable for Clinical Protein Quantitation
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Instruments, Applications Powering Rise of MALDI-MS as Clinical Proteomics Platform
January 20, 2012 / ProteoMonitor - SISCAPA-Based Biomarker Quantitation Moving to MALDI MS in Pursuit of Higher Throughput, Lower Costs
December 2, 2011 / ProteoMonitor - MALDI, Other Surface Sampling Methods Continue to Make Inroads in Clinical, Quantitative Proteomics
November 9, 2012 / ProteoMonitor - Targeted Mass Spec Slowly but Steadily Moving Toward Broader Commercial, Clinical Adoption
September 21, 2012 / ProteoMonitor - BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
June 8, 2012 / ProteoMonitor